aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
View original at globenewswire.com“Ended the first quarter 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments. Cash, cash equivalents, restricted cash and available-for-sale investments as of March 31, 2026, were $68.3 million.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
ATYR0101 selectively induces myofibroblast apoptosis via modulation of focal adhesion kinase (FAK) signaling through a novel binding interaction with LTBP-1 and results in a significant reduction of fibrosis in lung and kidney models
60% confidenceaTyr plans to file an IND in June 2026 for a new Phase 3 study in pulmonary sarcoidosis utilizing FVC as primary endpoint and KSQ-Lung score as key secondary endpoint
60% confidencePulmonary sarcoidosis and other forms of ILD have high unmet medical need with limited therapeutic options
60% confidenceThe planned Phase 3 trial will be a global, randomized, double-blind, placebo-controlled 54-week study with two parallel cohorts randomized to 5.0 mg/kg efzofitimod or placebo IV every 3 weeks for 17 doses, enrolling approximately 372 patients with restrictive pulmonary sarcoidosis on stable corticosteroid/immunosuppressant background
60% confidenceaTyr ended Q1 2026 with $68.3 million in cash, cash equivalents, restricted cash and investments
60% confidence2026 is off to a productive start with a clear path forward for efzofitimod in pulmonary sarcoidosis following the Type C FDA meeting
60% confidenceaTyr is on track to complete enrollment in the Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD in the first half of 2026
60% confidenceaTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation
60% confidenceEfzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis
60% confidence